X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Tata Investment Corporation - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TATA INVEST. CORP. - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

TATA INVEST. CORP. 
   Change

Tata Investment Corporation is more than 70 years old. It is a non banking financial company (NBFC). The stated objective of the company is to invest in Tata and non-Tata companies, both in the listed and unlisted categories. However, investments in ... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TATA INVEST. CORP. INDOCO REMEDIES/
TATA INVEST. CORP.
 
P/E (TTM) x 32.6 23.8 136.6% View Chart
P/BV x 3.9 2.2 172.6% View Chart
Dividend Yield % 0.6 1.9 30.1%  

Financials

 INDOCO REMEDIES   TATA INVEST. CORP.
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
TATA INVEST. CORP.
Mar-14
INDOCO REMEDIES/
TATA INVEST. CORP.
5-Yr Chart
Click to enlarge
High Rs360505 71.4%   
Low Rs249348 71.7%   
Sales per share (Unadj.) Rs119.039.6 300.9%  
Earnings per share (Unadj.) Rs8.433.8 24.7%  
Cash flow per share (Unadj.) Rs15.233.8 45.0%  
Dividends per share (Unadj.) Rs1.6017.00 9.4%  
Dividend yield (eoy) %0.54.0 13.2%  
Book value per share (Unadj.) Rs70.7390.3 18.1%  
Shares outstanding (eoy) m92.1555.10 167.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.610.8 23.8%   
Avg P/E ratio x36.412.6 289.0%  
P/CF ratio (eoy) x20.012.6 158.8%  
Price / Book Value ratio x4.31.1 394.6%  
Dividend payout %19.150.3 38.0%   
Avg Mkt Cap Rs m28,08323,489 119.6%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,16778 2,767.2%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,9682,180 503.2%  
Other income Rs m4024 168.2%   
Total revenues Rs m11,0072,203 499.6%   
Gross profit Rs m1,5652,021 77.4%  
Depreciation Rs m6331 57,527.3%   
Interest Rs m620-   
Profit before tax Rs m9092,044 44.5%   
Minority Interest Rs m0-1 0.0%   
Prior Period Items Rs m0112 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139292 47.5%   
Profit after tax Rs m7711,863 41.4%  
Gross profit margin %14.392.7 15.4%  
Effective tax rate %15.314.3 106.8%   
Net profit margin %7.085.5 8.2%  
BALANCE SHEET DATA
Current assets Rs m5,7252,676 213.9%   
Current liabilities Rs m5,4541,188 459.1%   
Net working cap to sales %2.568.3 3.6%  
Current ratio x1.02.3 46.6%  
Inventory Days Days620-  
Debtors Days Days723 2,421.7%  
Net fixed assets Rs m5,307136 3,905.4%   
Share capital Rs m184551 33.4%   
"Free" reserves Rs m6,33116,373 38.7%   
Net worth Rs m6,51621,506 30.3%   
Long term debt Rs m1,3230-   
Total assets Rs m11,97022,736 52.6%  
Interest coverage x15.6NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.1 955.7%   
Return on assets %7.08.2 84.9%  
Return on equity %11.88.7 136.6%  
Return on capital %12.410.0 123.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070 2,503,833.3%   
Fx outflow Rs m1,1410 2,853,500.0%   
Net fx Rs m3,3660 2,403,928.6%   
CASH FLOW
From Operations Rs m886840 105.5%  
From Investments Rs m-1,706-451 378.2%  
From Financial Activity Rs m1,316-1,032 -127.5%  
Net Cashflow Rs m497-643 -77.2%  

Share Holding

Indian Promoters % 59.2 73.0 81.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 4.5 277.8%  
FIIs % 6.0 1.5 400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 21.0 106.7%  
Shareholders   12,805 25,758 49.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   TALWALKARS BETTER VAL.  REDINGTON (INDIA)  GEOJIT BNP PARIBAS  KITEX GARMENTS  JSW HOLDINGS  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS